Ipsen (United States)

Recent papers from Ipsen (United States)

1. Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trialHepatology · 2026
2. Sex and racial disparities in clinical outcomes and health resource use among patients with primary biliary cholangitis in the United States.2026
3. Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trialJournal of Hepatology · 2026
4. Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’ESMO Open · 2026
5. Qualitative Evaluation of Fatigue and Pruritus Among Patients with Primary Biliary CholangitisAdvances in Therapy · 2026
6. Development of the Fibrodysplasia Ossificans Progressiva FLare EXperience Revised (FOP-FLEX-R©) Questionnaire: A Patient-Reported Outcome MeasureBone · 2026
7. Incidence, severity, and management of severe adverse events in first-line (1L) treatments for metastatic pancreatic ductal adenocarcinoma (mPDAC): A retrospective observational study.Journal of Clinical Oncology · 2026
8. Management of chemotherapy-induced adverse events in patients with metastatic pancreatic ductal adenocarcinoma: A US-based modified Delphi consensus.Journal of Clinical Oncology · 2026
9. First-line NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma and pre-existing diabetes: NAPOLI 3 post hoc analysis.Journal of Clinical Oncology · 2026
10. Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVELiver International · 2026
11. Botulinum toxin use in patients with neurological disorders: A U.S. ‐based claims database analysisPM&R · 2026
12. Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United StatesAdvances in Therapy · 2025
13. Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trialScientific Reports · 2025
14. P31 Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis (PBC): proteomic results from the ELATIVE® trialBMJ · 2025
15. Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter studyDevelopmental Medicine & Child Neurology · 2025
16. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trialESMO Open · 2025
17. Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiencyHepatology · 2025
18. Odevixibat for Episodic Intrahepatic Cholestasis due to Biallelic Mutations in ATP8B1 : A Case SeriesLiver International · 2025
19. Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialJournal of Hepatology · 2025
20. Burden of Comorbidities and Concomitant Medications and Their Associated Costs in Patients with Gastroenteropancreatic or Lung Neuroendocrine Tumors: Analysis of US Administrative DataAdvances in Therapy · 2025